

1 **Mendelian randomization suggests a causal link between glycemic traits and thoracic**  
2 **aortic structures and diseases.**

3 Tselmen Daria<sup>1</sup>, Kruthika Iyer<sup>1\*</sup>, Hasan Alkhairo<sup>1\*</sup>, Pik Fang Kho<sup>2,3\*</sup>, Ken Suzuki<sup>4,5,6,7</sup>,  
4 Konstantinos Hatzikotoulas<sup>8</sup>, Lorraine Southam<sup>8</sup>, Henry J Taylor<sup>9,10,11</sup>, Xianyong Yin<sup>12</sup>, Ravi  
5 Mandla<sup>13,14</sup>, Alicia Huerta-Chagoya<sup>14</sup>, Nigel W Rayner<sup>15</sup>, Michael G. Levin<sup>16,17</sup>, Scott M  
6 Damrauer<sup>18,19</sup>, Philip S Tsao<sup>3,20</sup>, James R Priest<sup>21</sup>, James Pirruccello<sup>22</sup>, Justin B Echouffo  
7 Tcheugui<sup>23</sup>, Catherine Tcheandjieu<sup>1,24,3</sup>

8  
9 <sup>1</sup>Gladstone Institutes of Data Science and Biotechnology, Gladstone Institute, 1650 Owens  
10 street, San Francisco, CA, 94158, USA, <sup>2</sup>Department of medicine, Division of Cardiovascular  
11 Medicine, Stanford University, 1650 Owens street, San Francisco, CA, 94158, USA, <sup>3</sup>VA Palo  
12 Alto Health Care System, CA, USA, <sup>4</sup>Centre for Genetics and Genomics Versus Arthritis,  
13 Division of Musculoskeletal and Dermatological Sciences, University of Manchester,  
14 Manchester, UK, <sup>5</sup>Centre for Musculoskeletal Research, University of Manchester, Manchester,  
15 UK, <sup>6</sup>Department of Diabetes and Metabolic Diseases,, University of Tokyo, Tokyo, Japan,  
16 <sup>7</sup>Department of Statistical Genetics, Graduate School of Medicine, Osaka University Graduate  
17 School of Medicine, Tokyo, Japan, <sup>8</sup>German Research Center for Environmental Health,  
18 Institute of Translational Genomics, Helmholtz Zentrum München, Neuherberg, Germany,  
19 <sup>9</sup>National Human Genome Research Institute, Center for Precision Health Research, National  
20 Institutes of Health, Bethesda, MD, USA, <sup>10</sup>Department of Public Health and Primary Care,  
21 Center for Precision Health Research, University of Cambridge, Cambridge, MD, UK, <sup>11</sup>Heart  
22 and Lung Research Institute, British Heart Foundation Cardiovascular Epidemiology Unit,  
23 University of Cambridge, Cambridge, MD, UK, <sup>12</sup>Department of Epidemiology, School of Public  
24 Health, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu, 211166, China,  
25 <sup>13</sup>Department of Medicine, Diabetes Unit, Endocrine Division,, Massachusetts General Hospital,  
26 Boston, MA, USA, <sup>14</sup>Programs in Metabolism and Medical and Population Genetics, Broad  
27 Institute of MIT and Harvard, Cambridge, MA, USA, <sup>15</sup>German Research Center for  
28 Environmental Health, Institute of Translational Genomics, Helmholtz Zentrum München,  
29 <sup>16</sup>Department of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania  
30 Perelman School of Medicine, 3400 Civic Center Blvd., Philadelphia, PA, 19104, USA,  
31 <sup>17</sup>Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, 19104, USA, <sup>18</sup>Department  
32 of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania Perelman School  
33 of Medicine, Philadelphia, PA, USA, <sup>19</sup>Corporal Michael Crescenz VA Medical Center,  
34 <sup>20</sup>Department of Medicine, Division of Cardiovascular Medicine, Stanford University, CA, USA,  
35 <sup>21</sup>Tenaya Therapeutics, South of San Francisco, CA, USA, <sup>22</sup>Division of Cardiology, University  
36 of California San Francisco, San Francisco, CA, USA, <sup>23</sup>Department of Medicine, John Hopkins  
37 University school of Medicine, Baltimore, MD, USA, <sup>24</sup>Department of epidemiology and  
38 Biostatistics, University of California San Francisco, San Francisco, CA, USA

39  
40 **Correspondence:** [Catherine.tcheandjieu@gladstone.ucsf.edu](mailto:Catherine.tcheandjieu@gladstone.ucsf.edu)

41 \*Authors contributed equally

42

43 **Abstract (max words count:350):**

44 **Importance:** Type 2 diabetes mellitus (T2DM) and elevated glucose levels have been inversely  
45 associated with aortic aneurysms. However, the causality of this relationship remains uncertain.  
46 Additionally, there is a lack of studies investigating the association between glycemic traits and  
47 imaging-based thoracic aortic phenotypes.

48 **Objective:** We investigated whether T2DM and glycemic measures (fasting glucose (FG), fasting  
49 insulin (FI), glycated hemoglobin (HbA1c), and 2-hour post-load glucose (2hPG)) are causally  
50 associated with various imaging and clinical thoracic aortic phenotypes.

51 **Design, setting, and participants:** We performed Mendelian randomization (MR) analysis using  
52 summary statistics from genome-wide association studies of glycemic traits (GT) and aortic  
53 phenotypes. We employed a two-sample univariate MR (UVMR) followed by a multivariable MR  
54 and MR analysis using a cluster-based approach.

55 **Main Outcomes and Measures:** The outcome includes imaging-based ascending and  
56 descending aortic diameters (AAoD and DAoD), aortic distensibility (AoDist) and strain (AoStr),  
57 and thoracic aortic aneurysm and dissection (TAAD). The GT include FI, FG, HbA1c, 2hPG and  
58 T2DM.

59 **Results:** We observed an inverse association between 2hPG, FG, HbA1c, and T2DM and AAoD,  
60 DAoD. For instance, the genetically predicted increases levels of 2hPG, FG, HbA1c, and T2DM  
61 were associated with decreased AAoD (2hPG  $\beta = -0.2$ ,  $p = 3 \times 10^{-08}$ ; FG  $\beta = -0.21$ ,  $p = 5 \times 10^{-05}$ ; HbA1c  
62  $\beta = -0.36$ ,  $p = 2 \times 10^{-07}$ ; T2DM  $\beta = -0.04$ ,  $p = 2 \times 10^{-04}$ ) and reduce risk TAAD (2hPG decreased TAAD  
63 (2hPG OR= 0.70,  $p = 4 \times 10^{-04}$ ; FG OR= 0.58,  $p = 3 \times 10^{-05}$ ; HbA1c OR= 0.62,  $p = 5 \times 10^{-03}$ ; T2DM OR=  
64 0.90,  $p = 6 \times 10^{-6}$ ). Further investigation showed that the inverse association between T2DM and  
65 aortic phenotypes is driven by genetic predictors of T2DM beta cell proinsulin clusters. UVMR  
66 and Proteomic MR showed a strong association with aortic phenotypes for genes, such as *AGER*,  
67 *GLRX*, *TCF7L2*, and *GCK*, which are known to play an important role in glucose regulation.

68 **Conclusion and relevance:** Our findings suggest a potentially causal impact of GT on the aortic  
69 vasculature. Furthermore, specific glucose regulation genes such as *GCK*, *AGER*, and *TCF7L2*  
70 appear to contribute to this process, opening avenues for potentially leveraging the druggability  
71 of these genes for treatment or preventions of TAAD.

72

## 73 INTRODUCTION

74 Aortic aneurysm and dissection involve weakening or balloon-like dilation in the aorta's wall,  
75 often asymptomatic until dissection occurs. These dissections, associated with high mortality  
76 rates, result in death in over 90% of cases within 48 hours if untreated<sup>1</sup>. The only curative  
77 treatment available is surgical; drug-based preventive therapies are lacking, highlighting a huge  
78 unmet need for clinical practice. Thoracic aortic aneurysm and dissection (TAAD) is generally  
79 linked to genetic disorders of the extracellular matrix and the contractile apparatus but also shares  
80 cardiovascular risk factors including male gender, age, smoking, hypertension, and  
81 hyperlipidemia<sup>2</sup>. Deep learning has enabled large-scale cardiac phenotyping including aortic  
82 measures in biobanks like UK Biobank<sup>3</sup>. Conducting genome-wide association studies (GWAS)  
83 on Magnetic Resonance Imaging (MRI)-derived aortic measures has led to the identification of  
84 genetic markers linked to aortic morphology and function. These discoveries have enhanced our  
85 understanding of the biology and genetics of aortic aneurysms and dissections<sup>4,5</sup>. Intriguingly,  
86 epidemiological studies have shown an inverse association between type 2 diabetes (T2DM) and  
87 TAAD<sup>6,7</sup>, however, the causal nature of this relationship remained unknown. A better  
88 understanding of the mechanisms underlying the negative association could help the  
89 development of innovative diagnostic and therapeutic approaches.

90 Observational studies can be marred with various types of errors such as confounding,  
91 reverse causation, mediation bias, or inability to fully differentiate the direct effect of T2DM on  
92 aortic aneurysms independent of upstream factors such as obesity and hypertension. Moreover,  
93 extant epidemiological studies have seldom examined the full spectrum of GT related to T2DM,  
94 such as insulin markers, glycated hemoglobin (HbA1c), fasting blood glucose (FG), and 2hour  
95 post glucose load (2hPG), which may offer unique insight into the link between dysglycemia and  
96 aortic structure and TAAD. However, very few studies have examined imaging-based subclinical  
97 aortic structure, that could indicate earlier stages of the aortic disease process.

98 Mendelian randomization (MR) utilizes genetic variations associated with exposures to assess  
99 potentially causal relationships between exposures and outcomes while controlling for  
100 confounding factors<sup>8</sup>. We aimed to investigate whether T2DM and various glycemic traits (FG, FI,  
101 HbA1c, and 2hPG) affect thoracic aortic structure and subsequently influence the development  
102 of TAAD using a comprehensive multi-omic approach. This approach includes an MR analysis  
103 across multiple populations, an innovative clustering-based MR analysis, proteomic MR,  
104 transcriptome-wide association (TWAS), and gene/pathway enrichment analysis.

## 105 **METHODS**

### 106 **Study population.**

107 All epidemiological analyses were conducted using data from the UK Biobank (UKBB) under  
108 application number 87,255. We analyzed approximately 30,000 participants who had undergone  
109 cardiac MRI, from which aortic phenotypes were extracted. To examine the association with  
110 TAAD, we utilized the full cohort of UKBB participants (1,135 cases /405,574 controls).

111 For the MR analysis, genetic summary statistics (SumStat) of associations between genetic  
112 variants and MRI-derived aortic phenotypes were obtained from approximately 39,000 UKBB  
113 participants from the European population (EUR)<sup>4,9</sup>. We sourced the SumStat for TAAD<sup>10</sup> from  
114 the Million Veteran Program (MVP) for EUR (7,050 cases/ 330,610 controls), African (AFR) (1,266  
115 cases/ 88,107 controls), and Hispanic (HIS) (310 cases/ 34,326 controls) populations. The GT  
116 exposure SumStats were derived from the population-specific GWAS of BMI adjusted- FG, FI,  
117 HbA1c, or 2hPG in EUR, AFR, and HIS<sup>11</sup>. The GT GWAS were performed in participants with no  
118 diabetes diagnosis, no reported use of diabetes-relevant medication(s); and who had an  
119  $FG \leq 7$  mmol/L (126 mg/dL),  $2hPG \leq 11.1$  mmol/L (200 mg/dL) or  $HbA1c \leq 6.5\%$ . IVs for T2DM  
120 were selected from EUR, HIS, and AFR-specific meta-analysis of T2DM adjusted on BMI<sup>12,13</sup>. To  
121 avoid sample overlap, we assess the association between T2DM and MRI-derived aortic  
122 phenotypes using EUR-only Sumstat which did not include the UKBB data. For the association

123 between T2DM and TAAD, we employed T2D population specific SumStat for EUR, AFR, and  
124 HIS that did not include data from the Million Veteran Program. The GWAS sample size for GWAS  
125 for each trait in each population used in our MR is available in Table S1.

### 126 **Association analysis of aortic phenotypes and glycemic traits**

127 First, we examined the epidemiological association of GT, including binary T2DM status, with  
128 aortic phenotypes including TAAD in the UKBB. We utilized blood glucose levels at enrollment,  
129 specifically random glucose (due to the small number of UKBB participants with both fasting  
130 glucose and MRI-derived aortic phenotypes) and HbA1c, and defined T2DM using International  
131 Classification of Diseases 10 (ICD-10) code, self-reported medical history and self-reported  
132 medication usage for diabetes (Table S2). The MRI-derived aortic measures included the  
133 diameter of the ascending aorta (AAoD), descending aorta (DAoD), as well as the distensibility of  
134 the ascending (AAoDis) and descending (DAoDis) aorta. These parameters were derived using  
135 image segmentation of the transversal image of cardiac MRI, sourced from an extensive dataset  
136 of over 1M images obtained from ~39,000 UKBB participants<sup>4,9,14</sup>. Phenotyping of TAAD was  
137 defined using ICD-10 codes, OPCS codes, and self-reported medical history (Table S2).

138 The associations between GT and MRI-derived aortic phenotypes were assessed using  
139 multivariable linear regression models while the association between GT and TAAD was  
140 assessed using multivariable logistic regression. All analyses were adjusted on body surface area  
141 (BSA) at imaging, sex acquired from the central registry at recruitment, lipids level and blood  
142 pressure (measured at enrollment), and age at the time of imaging or at enrollment. To mitigate  
143 potential confounding by indication, adjustments were made for participants taking  
144 antihypertensive medication by adding 10 mmHg to diastolic blood pressure and 15 mmHg to  
145 systolic blood pressure<sup>15</sup>. For participants on lipid-lowering medications, raw LDL values were  
146 divided by 0.7 to account for medication influence on lipid levels<sup>16</sup>. Participants with diabetes  
147 medication usage were classified as T2DM cases.

148 **Mendelian randomization (MR) analyses**

149 **Selection of instrumental variables (IV).**

150 The IV was defined as SNP with minor allelic frequency (MAF)  $>0.05$ , independently associated  
151 with the exposure at the GWAS significance ( $p < 5 \times 10^{-08}$  and  $R^2 < 0.001$ ). However, to overcome  
152 power issues due to the small sample size in GWAS among AFR and HIS, we lowered the p-  
153 value threshold for selecting the IV to a suggestive threshold of  $p < 1 \times 10^{-05}$ . In a second approach,  
154 we performed an MR using SNPs that were selected as IVs in EUR and that were nominally  
155 significant ( $p < 0.05$ ) in non-EUR. Variants selected as instruments from the exposure GWAS  
156 SumStat were then matched to the outcome SumStat. Given the lack of data available for aortic  
157 measures in non-EUR, we performed the MR of GT and aortic measurements among EUR-only,  
158 while the MR between GT and TAAO was performed independently in EUR, AFR, and HIS.

159 **Statistical analyses**

160 Figure 1 presents the analysis flowchart. For each exposure-outcome pair, the IV was harmonized  
161 to ensure consistency of the effect allele between the exposure and the outcome. An IV was  
162 excluded if its variance, as explained by the F statistic, was less than 10 ( $F < 10$  indicates a weak  
163 IV) if the MAF  $< 0.05$ , or if the SNP appeared to be multi-allelic. Additionally, we used MR-Steiger  
164 filtering to exclude SNPs indicating possible reverse causation or for which the effect on the  
165 outcome is larger than the exposure<sup>17</sup>. The inverse-variance weighted (IVW) method was used  
166 as the primary analytical approach to assess the relationship between each exposure-outcome  
167 pair. The IVW method is considered most powerful because it depends on the validity of all IVs  
168 and can robustly detect associations<sup>18</sup>. To investigate heterogeneity, we used the Cochran Q  
169 method. The MR-Presso global test was conducted to examine the presence of heterogeneous  
170 SNPs, identify outliers, and correct for horizontal pleiotropy<sup>19</sup>. In sensitivity analyses, we  
171 employed MR-Egger, weighted median, and inverse weighted median methods. The MR-Egger  
172 intercept test was specifically utilized to detect potential directional pleiotropy, where the MR-



173 Egger intercept can be interpreted as an estimate of the average horizontal pleiotropic effect of  
174 the genetic variants<sup>20</sup>.

175 To address the high likelihood of pleiotropy between GT genetic variants (that is, variants affecting  
176 multiple GT simultaneously), we conducted a multivariable MR analysis using MVMR in R<sup>21</sup>. This  
177 analysis included all evaluated GTs (FG, FI, 2hPG, and HbA1c) and T2DM for each outcome.  
178 Additionally, we performed MVMR incorporating all evaluated GTs and T2DM, along with blood  
179 pressure (SBP, DBP) and lipid biomarkers (LDL, HDL) to account for potential confounders in the  
180 relation between GT and aortic phenotypes. For exposures and outcomes showing significant  
181 heterogeneity after pleiotropy assessment, reverse causation testing and outlier correction, we  
182 employed a clustering approach with MR-Clust<sup>22</sup>. MR-Clust clusters genetic variants based on  
183 their causal effect estimates and define clusters assuming distinct causal mechanisms.

184 To explore the potential biological mechanisms relevant to T2DM driving the observed inverse  
185 association with aortic phenotypes, we leveraged the T2DM mechanistic clusters defined by  
186 Suzuki et al<sup>13</sup> for MR. These T2DM mechanistic clusters were derived using a combination of  
187 dimension reduction and hard clustering of T2DM lead SNPs and their significant association with  
188 cardiometabolic traits such as FG, HbA1c, BMI, obesity, blood pressure, lipids biomarkers, and  
189 fat tissue percentage<sup>13</sup>. The defined clusters include Beta cell +PI (Proinsulin; 91 SNPs), Beta cell  
190 -PI (89 SNPs), Residual glycemc (389 SNPs), Body fat (273 SNPs), metabolic syndrome (166  
191 SNPs), obesity (233 SNPs), lipodystrophy (45 SNPs), liver and lipid metabolism (3 SNPs). For  
192 each of these clusters, we performed an MR analysis with MRI-derived aortic phenotypes and  
193 TAAD.

#### 194 **Evaluation of the MR assumption**

195 Overall, to ensure that robust conclusions are derived, we rigorously tested the three core MR  
196 assumptions: relevance, exchangeability, and exclusion restriction. The relevance assumption



197 was validated by assessing the strength of IV by excluding instruments with an F statistic below  
198 10 to avoid weak instrument bias. The exchangeability assumption was addressed through  
199 multivariable MR analysis<sup>21</sup> to distinguish genuine gene-disease associations from spurious ones  
200 caused by confounding genetic variants<sup>23</sup>. Finally, the exclusion restriction assumption was  
201 examined using MR-Steiger filtering<sup>17</sup>, which helps confirm that the genetic predictors influenced  
202 the outcome solely through exposure.

### 203 **Mendelian Randomization of pQTLs and GT as well as aortic phenotypes**

204 To investigate the colocalization of protein quantitative trait loci (pQTLs) and GT as well as aortic  
205 phenotypes, we employed summary-data-based Mendelian Randomization (SMR) and the  
206 heterogeneity in dependent instruments (HEIDI) test<sup>24</sup>. GWAS of 2,940 plasma proteins were  
207 sourced from the genetically inferred EUR in the UK Biobank<sup>25</sup>. *cis*-pQTLs were defined as SNPs  
208 located 1 Mb upstream and downstream of the protein-coding genes, demonstrating an  
209 association with plasma protein levels at  $P < 3 \times 10^{-05}$ . Multi-allelic SNPs were excluded before the  
210 SMR analysis. We conducted SMR analysis integrating GWAS with pQTL data from the UKBB  
211 with GWAS of GT, T2DM and aortic phenotypes from EUR. The EUR population in the 1000  
212 Genomes Project was used as the reference to estimate the linkage disequilibrium between  
213 SNPs. The HEIDI test was then applied to differentiate pleiotropic associations from those due to  
214 linkage. Associations passing the Bonferroni-corrected significance threshold in SMR analysis  
215 and the HEIDI  $P > 0.05$  were considered robust evidence for colocalization between pQTLs and  
216 GWAS.

### 217 **Functional annotation of IVs and transcriptome-wide association studies**

218 To explore the biological implications of GT genetic variants, we first annotated each SNP  
219 selected as IV using various annotation tools including Phenoscanner<sup>26</sup>, SNP Nexus<sup>27</sup>, and  
220 Haploreg<sup>28</sup>. These annotations include eQTL expression look-up for each SNP in various tissues  
221 (such as aorta, arteries, heart, and fibroblasts), with eQTL data sourced from GTEx and

222 STARNET<sup>29,30</sup>. A significant eQTL mapping was defined as an SNP with tissue eQTL p-value <  
223  $1 \times 10^{-05}$ . To further extend our eQTL mapping to genes targeted by our IVs, we performed a  
224 transcription-wide association (TWAS) study on all GT traits GWAS using S-PrediXcan, a  
225 summary-statistics-based gene mapping method available in the MetaXcan software package<sup>31</sup>.  
226 The summary statistics were harmonized following the best practices on MetaXcan GitHub  
227 (<https://github.com/hakyimlab/MetaXcan>). Using a precomputed expression prediction model  
228 utilizing the GTEx database, we inferred tissue-specific gene-trait associations<sup>30</sup>. Tissues tested  
229 include coronary artery, aorta, visceral and subcutaneous adipose, atrial appendage, left  
230 ventricle, liver, pancreas, whole blood, and EBV-transformed lymphocyte cells. In sensitivity  
231 analyses, we used two different families of prediction models, elastic net-based and MASHR-  
232 based, a biologically informed model<sup>32</sup>. For each trait, FDR p-value correction was conducted  
233 both by tissue and across all tested tissues.

### 234 **Gene enrichment analysis**

235 Significant genes from S-PrediXcan that were also gene targets by the IVs in our MR, were tested  
236 for GO-term overrepresentation using the enrichGO function within the clusterProfiler package<sup>33</sup>.  
237 The analysis was performed for each ontology (molecular function, biological process, and cellular  
238 component) and significant genes from each trait-tissue pair separately. The universe of genes  
239 for each enrichment analysis was defined as genes present in the GTEx tissues summary statistic  
240 files. The p-values were corrected using the Benjamini-Hochberg method.

## 241 **RESULTS**

### 242 **Epidemiological association between GT and aortic phenotypes in the UKBB**

243 The characteristics of our study population are described in Table ST2. We observed an inverse  
244 association of HbA1c and T2DM with ascending and descending aortic diameters as well as  
245 TAAD risk (Table 1). The inverse association with HbA1c was even stronger among participants  
246 without diabetes (Table 1, Table ST4).

## 247 **MR Glycemic traits and aortic phenotypes**

### 248 **Aorta diameter and thoracic aortic aneurysm**

249 In univariate MR analyses using the IVW method, 2hPG, FG, HbA1c, and T2DM were all inversely  
250 associated with AAOd and DAoD but no association was observed with FI (Table S5-6, Figure 2).  
251 Notably, the associations of 2hPG, FG, HbA1c, and T2DM with AAOd were significant (Table S6,  
252 Figure 2), whereas only the associations of 2hPG and FG with DAoD were significant (Figure 2).  
253 We also observed a significantly inverse association of 2hPG, FG, HbA1c, and T2DM with TAA  
254 (Table S6, Figure 2). These observed association with TAA in Europeans were similarly present  
255 among AFR and HIS populations (Figure S3, Table ST6). However, only the association with  
256 T2DM in HIS reached statistical significance ( $\beta$ : -0.35,  $p=7 \times 10^{-03}$ ) (Table ST6, Figure S3). In  
257 sensitivity analyses, a consistent inverse association was observed using MR Egger, weighted  
258 median, and weighted modal approaches, which aligned with the aforementioned IVW results  
259 (table S5-6, Figure S2).

260

261 In multivariable MR analyses, the inverse associations remained significant for 2hPG and AAOd  
262 ( $\beta$ : -0.11,  $p=2 \times 10^{-5}$ ); HbA1c and AAOd ( $\beta$ : -0.37,  $p=4 \times 10^{-03}$ ); 2hPG and DAoD ( $\beta$ : -0.08,  $p=5 \times 10^{-$   
263  $04$ ); 2hPG and TAA ( $\beta$ : -0.27 (OR=0.76),  $p=2.3 \times 10^{-05}$ ); FG and TAA ( $\beta$ : -0.26 (OR=,  $p=3.5 \times 10^{-$   
264  $02$ ); and T2DM and TAA ( $\beta$ : -0.07,  $p=2 \times 10^{-02}$ ) (Figure1, Table ST7). It is noteworthy that some  
265 exposures had weak strength of the genetic instruments (F-statistics <10, Table ST7) due to a  
266 large number of SNPs used as IVs in the T2DM analysis. In a sensitivity analysis using a different  
267 summary statistic with smaller number of genetic instruments for T2DM, we observed similar  
268 results with most exposures displaying strong genetic instruments (Table ST8).

### 269 **Aortic strain and distensibility**

270 In univariate MR analyses using IVW, we observed that 2hPG exhibited an inverse association  
271 with both DAoDis and AAODis ( $\beta$  = -0.12,  $p = 7.5 \times 10^{-5}$  and  $\beta$  = -0.11,  $p = 3.1 \times 10^{-3}$ , respectively;

272 see Figure 2). FG and T2DM were significantly associated with DAoDis ( $\beta = -0.12$ ,  $p = 4 \times 10^{-3}$   
273 and  $\beta = -0.03$ ,  $p = 5 \times 10^{-3}$  for FG and T2DM, respectively). Regarding aortic strain (AoSt), FI and  
274 HbA1c demonstrated a significant association with strain in the ascending aorta (Figure 2). In  
275 multivariable MR analyses, the association between 2hPG and DAoDis remained significant, and  
276 the associations between AAoSt and either FI or HbA1c also persisted (Figure 2).

### 277 **Heterogeneity and Sensitivity Analysis**

278 Significant variability was detected using the Q statistic for the associations between DAoD and  
279 HbA1c; TAAO and T2DM; and FI with both AAoD and DAoD (Table ST5), despite addressing  
280 reverse causation, excluding weak instruments, correcting for horizontal pleiotropy and removing  
281 outliers. However, consistent directionality of effects was observed across MR IWW, MR Egger,  
282 weighted median, and weighted modal approaches for most exposure-outcome traits (Table ST5,  
283 Figure S2-4).

### 284 **MR using the clustering approach**

285 Given that the observed heterogeneity suggests a potential contradiction in the effect direction of  
286 the SNPs included in each analysis, we reclassified our IVs into more homogenous groups using  
287 a cluster analysis approach and conducted MR within each cluster. We identified, for the outcome  
288 AAoD, DAoD, and TAAO, and the exposure HbA1c, FG, and FI respectively, two distinct clusters  
289 of associations (Table ST9, Figure 3(a)). These clusters included either one with a positive  
290 association and another with a negative association, or two unique clusters with negative  
291 associations. For instance, the inverse relationship between FG and AAoD showcased two  
292 clusters with inverse associations, of which only one cluster, comprising 20 IVs, was significant  
293 ( $\beta=-0.88$ ,  $p=8.02 \times 10^{-20}$ , Figure 3(a)) while the inverse association with the second cluster  
294 including 48 IV was not significant (Table ST9, Figure 3(a)). The associations between FI and  
295 both AAoD and DAoD, which were non-significant in our overall MR analysis, revealed two distinct  
296 clusters with significant associations. One cluster displayed a positive association, while the other

297 showed an inverse association (Figure 3a). This indicates that a subset of insulin-related genetic  
298 instruments may contribute to an increase in aortic diameter, while another set may be linked to  
299 a decrease in aortic diameter. Similarly, we observed two distinct clusters with significant  
300 associations in opposite directions for FG/TAAD and T2DM/TAAD exposure-outcome pairs. This  
301 suggests that the impact of FG or T2DM on TAAD may operate through distinct biological  
302 pathways, which are either protective or detrimental.

### 303 **MR using T2DM predefined cluster**

304 To further explore the biological processes linking T2DM to MRI-derived aortic phenotypes and  
305 TAAD, we conducted MR between aortic phenotypes and clusters of SNPs representing various  
306 biological processes implicated in T2DM pathophysiology, as recently described by Suzuki et al  
307 <sup>13</sup>. We found that the beta-cell (+) proinsulin cluster (beta-cell +PI) and the beta-cell (-) proinsulin  
308 (beta-cell -PI), characterized by variants that reduce insulin secretion and enhance insulin  
309 sensitivity, were significantly inversely associated with AAoD, DAoD, and TAAD (Figure 3b, Table  
310 ST10). These associations were most pronounced for the beta-cell -PI clusters. Furthermore, the  
311 metabolic syndrome cluster (dominated by fasting glucose, fasting Insulin, visceral adipose  
312 tissues, and Glutamine fructose-6-phosphate amidotransferase [GFAT] genes) was inversely  
313 associated with AAoD, DAoD, and TAAD, while the obesity cluster was significantly associated  
314 with larger DAoD (Figure 3b, Table ST10). Additionally, the lipodystrophy cluster, enriched with  
315 body fat, lipid levels, and blood pressure, were associated with an increase in AAoD, DAoD, and  
316 TAAD (although the association was not significant), while decreasing strain and distensibility of  
317 both ascending and descending aorta (Figure 3b and Figure S5).

### 318 **Proteomic mendelian randomization**

319 To better understand the link between glycemic traits and aortic phenotype, we also assessed  
320 the impact of proteomic biomarkers on aortic structure and diseases. We performed SMR  
321 between UKBB 2940 Olink pQTL and aortic phenotypes and identified few pQTL associated with

322 aortic phenotypes (Table ST13, Figure 4a and Figure S6). For instance, COL6A3 pQTL was  
323 inversely associated with AAOd, DAoD, and TAAAD (Figure 4a). FGF5 pQTL was associated with  
324 AAOd and AAostr, AGER, ECM1, and IGFBP3 were associated with DAoD, DAoStr, and DAdis  
325 respectively (Figure 4a). Other pQTL with significant SMR association includes FADD, GLRX,  
326 and AOC3 which are all pQTL biomarkers for cardiometabolic profile (Table ST13). To investigate  
327 whether pQTLs associated with GT are also associated with aortic phenotype, we performed SMR  
328 analysis for FG, 2hPG, FI, and HbA1c. We then checked for overlap between pQTLs showing  
329 significant SMR associations with both aortic phenotypes and GT. We identified 12 proteins  
330 associated with HbA1c, 4 proteins associated with FG, 3 proteins for FI, and one protein for 2hPG  
331 (Table ST13). Among these identified proteins, only ABO which was associated with 2hPG, was  
332 also associated with DAoSt (Table ST13). No other proteins with significant association with GT  
333 were also associated with aortic phenotypes. When investigating whether SNPs in these pQTL-  
334 associated genes have IVs in our MR, we found that SNPs in or near ABO and AGER were  
335 present in the UVMR.

### 336 **Functional annotation and enrichment Analysis of Selected Genetic Instruments**

337 Functional annotations of SNPs selected as IVs are available in Table S10 and S16. Overall, we  
338 observed that several of our IVs are located in regulatory regions such as promoter/enhancer  
339 histone marks, proteins bound, or altered transcription factors binding motifs. Several of our IVs  
340 were also missense (ex: rs267738 in CESR2, rs120326 in GCKR, and rs1800562 in HFE),  
341 nonsynonymous variants or variants located in 5'UTR of genes. We also observed that several  
342 IVs have significant eQTL changes in various heart-related tissues including the aorta (Table  
343 S13). For instance, SNPs selected as IVs in GCK, TCF7L2, HFE, ABCC8, and AGER, showed  
344 significant eQTL in heart and aortic tissues (Table S13). Our TWAS analysis unveiled a significant  
345 enrichment ( $p < 1 \times 10^{-05}$ ) of genes surrounding our IVs for FG, HbA1c, and T2DM across a range  
346 of tissues and cells including the aorta, tibial artery, heart, whole blood, and fibroblasts (Table

347 ST13). When specifically examining the TWAS in aortic tissues, we observed a significant  
348 association between various GT and changes in gene expression of *GCK*, *CTSS*, *HFE*, *KHK*,  
349 *AGER*, and *TCF7L2* (Figure 4(b) and Table ST14). Moreover, our gene ontology enrichment  
350 utilizing gene targets by our IVs and with notable eQTL expression in aortic tissues showcased a  
351 significant enrichment in gene ontology pathways such as carbohydrate kinase activity, glucose  
352 homeostasis, intracellular glucose homeostasis, and positive regulation of hormone secretion  
353 (Table ST15). Genes playing a key role in these pathways include *TCF7L2*, *GCK*, *HFE*, *KHK*, and  
354 *AGER*.

## 355 **DISCUSSION**

356 In this study, we comprehensively assessed the relationship between glycemic traits and aortic  
357 phenotypes, using an epidemiological approach, followed by a comprehensive MR across  
358 multiple populations, and a multi-omics analysis. Genetic predictors associated with high fasting  
359 glucose, HbA1c, 2-hour post-load glucose, and T2DM risk were linked to a decrease in aortic size  
360 and a reduced risk of TAAD. In particular, the inverse association with T2DM may be driven by  
361 genetic variants associated with beta-cell function. Moreover, glucose regulation genes such as  
362 *GCK* and *TCF7L2* are potentially involved in biological processes conferring a protective effect  
363 on aortic aneurysm.

364 Our study confirmed and expanded the inverse epidemiological associations between glycemic  
365 measures and aortic phenotypes observed in prior research. For instance, increased arterial  
366 stiffness, reduced aortic elasticity, and lower rates of development, progression, and mortality  
367 from aortic aneurysms have been noted individuals with prediabetes or diabetes<sup>34–36</sup>.  
368 Furthermore, among men, an inverse relationship has been observed between high fasting  
369 glucose levels and infra-aortic diameter on one hand, and the risk of abdominal aortic aneurysm  
370 (AAA) progression on the other hand<sup>37</sup>. Our MR analyses indicated that genetically predicted  
371 T2DM risk, higher HbA1c, FG, and 2hPG levels are associated with smaller AAoD, DAoD, and



372 lower risk of TAAD; consistent with previously reported MR studies that examined the impact of  
373 GT on TAAD and MRI-derived aortic structure<sup>38,39</sup>. We also showed, for the first time, an inverse  
374 association between GT and TAAD among African and Hispanic populations. However, the  
375 association was only significant for T2DM in a Hispanic subgroup, probably due to a lack of power  
376 driven by insufficient sample size in ancestry-specific summary statistics.

377 An innovative aspect of our analysis is the application of MR on clusters of genetic variants, which  
378 allowed testing the hypothesis of the co-existence of different directional effects within our GT  
379 instruments, attributable to distinct biological and molecular pathways. Our approach revealed  
380 that certain IVs associated with FG, FI, and HbA1c may correlate with an increase in aortic  
381 diameter and TAAD risk. Conversely, other IVs associated with these GTs, were associated with  
382 a decreased in aortic diameter and TAAD risk. For instance, within the cluster of genetic variants  
383 showing an inverse association for FG and HbA1c, we identified variants in genes such as *GCK*  
384 and *TCF7L2*. Indeed, prior studies have suggested that variants in *TCF7L2* and *GCK* are linked  
385 to a decreased risk of aortic aneurysm or macrovascular disease<sup>10,40,41</sup>. On the other hand, among  
386 variants in the FI cluster associated with a larger aorta diameter or higher risk of TAAD, we noted  
387 the variant rs284585 in *VEGF*, a vascular endothelial growth factor. *VEGF* is a well-known protein  
388 that causes vascular endothelial cells to proliferate, migrate, and become more permeable<sup>42</sup>.  
389 Moreover, findings suggest that insulin's action may enhance angiogenesis through *VEGF* and  
390 promote vasodilation<sup>43</sup> thus possibly increasing the risk of TAAD.

391 We also utilized the cardiometabolic clusters defined by Suzuki et al<sup>13</sup> to investigate the  
392 relationship between various aspects of the T2DM metabolic profile and aortic phenotypes. We  
393 showed that clusters associated with beta-cell dysfunction—specifically those with a positive  
394 association with proinsulin (beta cell (+) PI) and a negative association with proinsulin (beta cell  
395 (-) PI)—were inversely correlated with aorta diameter and TAAD. Notably, the beta cell (-) PI  
396 cluster exhibited even stronger associations. Of note, the beta cell cluster was dominated by

397 genes/loci increasing FG, 2hPG, and HbA1c suggesting that factors affecting glucose  
398 homeostasis have a greater impact on aortic structure and function.

399 We enhanced our MR analysis by additionally conducting a proteomic MR approach, which offers  
400 additional insights into proteins involved, and thus potential mechanisms linking GT to aortic  
401 structure and disease. This approach helped shed light on the biological pathways contributing to  
402 observed genetic associations, thereby strengthening our findings and providing a  
403 comprehensive perspective on the molecular underpinnings of aortic phenotypes. Our SMR  
404 analysis identified several proteomic biomarkers associated with aortic phenotypes. Notably,  
405 *COL6A3* pQTL is associated with AAoD, DAoD, and TAAD while *AGER* pQTL is associated with  
406 DAoD. *AGER* or *RAGE* is a receptor that binds to advanced glycation end products (AGEs) for  
407 degradation. Chronic hyperglycemia leads to the formation of AGEs, which stabilize collagen  
408 networks, increase resistance to protease degradation, and reduce aortic wall stress<sup>7,43–45</sup>. In AAA  
409 tissues from individuals with diabetes, increased cross-linking AGEs like pentosidine correlate  
410 with smaller AAA diameters, indicating a protective role due to collagen network stabilization<sup>7,46</sup>.  
411 *COL6A3* is a core component of collagen type VI, which assembles into microfibrils, forming a  
412 scaffold within the extracellular matrix, thus supporting the aortic tissue structure by providing  
413 tensile strength and resilience against mechanical stress. *COL6A3* can undergo glycation in the  
414 setting of hyperglycemia. AGE-modified *COL6A3* in the aortic wall could contribute to increased  
415 vascular stiffness, influencing blood flow dynamics and vessel function<sup>47–49</sup>. Further studies are  
416 needed to better understand the relation between these protein biomarkers and aortic phenotype  
417 in hyperglycemic conditions.

418 Functional annotation of IVs revealed an enrichment of functional impact for multiple SNPs. this  
419 includes the presence of missense variants among our IVs, SNPs located in regulatory elements  
420 such as transcription factor binding sites, enhancers, and promoters active in aortic tissues. This  
421 includes SNPs in genes such as *GCK* that also show significant enrichment in aortic tissues from

422 our TWAS. *GCK*, a glucokinase linked to maturity-onset diabetes of the young (*MODY2*), a rare  
423 monogenic diabetes where elevated blood glucose levels remain stable without worsening  
424 glycemic control<sup>41,50</sup>. Studies have suggested that patients with *GCK*- *MODY2* exhibit a lower risk  
425 of diabetes-related micro- and macro-vascular complications<sup>41</sup>. Glucokinase activation, targeting  
426 *GCK*, has recently emerged as a potential diabetes therapy, which is either FDA approved  
427 (tofogliflozin) or tested in phase II or III clinical trials (ex: GKA-50 and dorzagliatin)<sup>51-54</sup>. In our  
428 study, SNPs in *GCK* were included as IVs for the HbA1c, FG, and the T2DM beta cell (-) PI cluster.  
429 Molecules targeting *GCK* in diabetes treatment could be good candidates for repurposing to  
430 TAA treatment and prevention given the impact of *GCK* on decreasing the aorta diameter.

431 Another interesting finding provided by MR, functional annotation and TWAS analysis in aortic  
432 tissue is the evidence to support the causal effect of *TCF7L2* gene on adverse aortic phenotypes.  
433 An inverse association between *TCF7L2* locus and TAA was previously described by  
434 Roychowshury et al<sup>40</sup>. However, in the latter study, the inverse association observed at the locus  
435 was driven by a set of variants also independently associated with an increased risk of diabetes.  
436 They suggested that the inverse association between T2DM and TAA at this locus reflects  
437 independent gene-level horizontal pleiotropy<sup>40</sup>. In our TWAS, *TCF7L2* gene expression in aortic  
438 tissues was inversely associated with HbA1c, FG, 2hPG, and T2DM. Furthermore, SNPs in  
439 *TCF7L2* including rs7903146 were IVs for 2hGP, HbA1c (-) association cluster, FG (-) association  
440 cluster as well as in the T2D beta cell (+) PI cluster. Indeed, rs7903146 is a known diabetes  
441 candidate SNP<sup>55</sup>. In our analysis, rs7903146 showed an inverse association with 2hPG, FG,  
442 HbA1c, and T2DM with the directionality of the effect consistent with the association of *TCF7L2*  
443 variants rs4077257 reported by Roychowshury et al<sup>40</sup>. A genetic correlation analysis conducted  
444 on a European population revealed a correlation coefficient ( $R^2$ ) of 0.46 between the genetic  
445 variants rs7903146 and rs4077257. Based on these findings, we hypothesize that the observed  
446 inverse association between the *TCF7L2* gene and aortic phenotypes may be mediated through

447 glucose levels, independent of diabetes status. Further research is warranted to investigate this  
448 hypothesis in greater detail.

449 Our pathway analyses identified several pathways with high enrichment of genes targeted by the  
450 IVs in our MR study. These pathways include carbohydrate kinase activity, glucose homeostasis,  
451 response to intracellular glucose homeostasis, response to monosaccharides, regulation of the  
452 glycolytic process, peptide secretion, and response to carbohydrates. Key genes involved are  
453 *GCK*, *TCF7L2*, *KHK*, *HFE*, and *AGER*. These interconnected pathways are crucial for maintaining  
454 glucose balance and cellular energy management. For example, carbohydrate kinase activity and  
455 glucose homeostasis regulate glucose levels and limit AGE formation. As mentioned above,  
456 accumulation of AGEs affects the extracellular matrix remodeling of the aortic wall by cross-linking  
457 with ECM proteins such as collagen and elastin which could increase aortic wall stiffness<sup>7</sup>. Thus,  
458 possibly contributing to the observed decreased risk of aortic aneurysm in diabetes and  
459 hyperglycemia.

#### 460 **Strengths and limitations**

461 To our knowledge, our study is the first to investigate the role of GT on TAAD among non-  
462 European populations. Furthermore, this is the first comprehensive study to assess the  
463 relationship between GT/diabetes and aortic phenotypes using a multi-omic approach that  
464 includes MR, clustering MR analysis, proteomic MR, TWAS, and gene/pathway enrichment  
465 analysis. The validity and robustness of our findings are supported using a two-sample MR  
466 technique with the latest GWAS summary statistics data available for exposure-outcome traits,  
467 supplemented by MR cluster analysis. A limitation of our study is that we could not assess the  
468 causal relationship between glycemic traits and aortic structure in non-European populations.  
469 However, our results showing an inverse association between glycemic traits and thoracic aortic  
470 aneurysm suggest that the direction of these associations is consistent across different  
471 ancestries.

472 **CONCLUSION**

473 Genetic predictors associated with high fasting glucose, HbA1c, 2-hour post-load glucose, and  
474 T2DM risk are causally linked to a decrease in aortic size and a reduced risk of TAAD. The inverse  
475 association with T2DM may be driven by genetic variants associated with beta-cell function. The  
476 study highlights the potential involvement of glucose regulation genes such as *GCK* and *TCF7L2*.  
477 Hence, drug targeting GCK such as glucokinase activators, or interacting with TCF7L2 such as  
478 metformin, could be potential good candidate to be repurposed for treating and preventing TAAD.  
479 Future preclinical/clinical research is needed to better understand this opportunity.

480

481 References

- 482 1. Elefteriades JA, Sang A, Kuzmik G, Hornick M. Guilt by association: paradigm for  
483 detecting a silent killer (thoracic aortic aneurysm). *Open Heart*. 2015;2(1):e000169.  
484 doi:10.1136/openhrt-2014-000169
- 485 2. Pinard A, Jones GT, Milewicz DM. Genetics of Thoracic and Abdominal Aortic Diseases.  
486 *Circ Res*. 2019;124(4):588-606. doi:10.1161/CIRCRESAHA.118.312436
- 487 3. Petersen SE, Matthews PM, Francis JM, et al. UK Biobank's cardiovascular magnetic  
488 resonance protocol. *J Cardiovasc Magn Reson*. 2016;18:8. doi:10.1186/s12968-016-0227-  
489 4
- 490 4. Pirruccello JP, Chaffin MD, Chou EL, et al. Deep learning enables genetic analysis of the  
491 human thoracic aorta. *Nat Genet*. 2022;54(1):40-51. doi:10.1038/s41588-021-00962-4
- 492 5. Benjamins JW, Yeung MW, Van De Vegte YJ, et al. Genomic insights in ascending aortic  
493 size and distensibility. Published online 2022. doi:10.1016/j
- 494 6. D'cruz RT, Wee IJY, Syn NL, Choong AMTL. The association between diabetes and  
495 thoracic aortic aneurysms. *J Vasc Surg*. 2019;69(1):263-268.e1.  
496 doi:10.1016/j.jvs.2018.07.031
- 497 7. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Diabetes and  
498 aortic aneurysm: current state of the art. *Cardiovasc Res*. 2018;114(13):1702-1713.  
499 doi:10.1093/cvr/cvy174
- 500 8. Minelli C, Del Greco M F, van der Plaats DA, Bowden J, Sheehan NA, Thompson J. The  
501 use of two-sample methods for Mendelian randomization analyses on single large  
502 datasets. *Int J Epidemiol*. 2021;50(5):1651-1659. doi:10.1093/ije/dyab084
- 503 9. Tcheandjieu C, Xiao K, Tejada H, et al. High heritability of ascending aortic diameter and  
504 trans-ancestry prediction of thoracic aortic disease. *Nat Genet*. 2022;54(6):772-782.  
505 doi:10.1038/s41588-022-01070-7
- 506 10. Klarin D, Devineni P, Sendamarai AK, et al. Genome-wide association study of thoracic  
507 aortic aneurysm and dissection in the Million Veteran Program. *Nat Genet*.  
508 2023;55(7):1106-1115. doi:10.1038/s41588-023-01420-z
- 509 11. Chen J, Spracklen CN, Marenne G, et al. The trans-ancestral genomic architecture of  
510 glycemic traits. *Nat Genet*. 2021;53(6):840-860. doi:10.1038/s41588-021-00852-9
- 511 12. Mahajan A, Spracklen CN, Zhang W, et al. Multi-ancestry genetic study of type 2 diabetes  
512 highlights the power of diverse populations for discovery and translation. *Nat Genet*.  
513 2022;54(5):560-572. doi:10.1038/s41588-022-01058-3
- 514 13. Suzuki K, Hatzikotoulas K, Southam L, et al. Genetic drivers of heterogeneity in type 2  
515 diabetes pathophysiology. *Nature*. 2024;627(8003):347-357. doi:10.1038/s41586-024-  
516 07019-6
- 517 14. Pirruccello JP, Rämö JT, Choi SH, et al. The Genetic Determinants of Aortic Distention. *J*  
518 *Am Coll Cardiol*. 2023;81(14):1320-1335. doi:10.1016/j.jacc.2023.01.044
- 519 15. Surendran P, Feofanova E V., Lahrouchi N, et al. Discovery of rare variants associated  
520 with blood pressure regulation through meta-analysis of 1.3 million individuals. *Nat*  
521 *Genet*. 2020;52(12):1314-1332. doi:10.1038/s41588-020-00713-x
- 522 16. Graham SE, Clarke SL, Wu KHH, et al. The power of genetic diversity in genome-wide  
523 association studies of lipids. *Nature*. 2021;600(7890):675-679. doi:10.1038/s41586-021-  
524 04064-3



- 525 17. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between  
526 imprecisely measured traits using GWAS summary data. *PLoS Genet.*  
527 2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081
- 528 18. Nikolakopoulou A, Mavridis D, Salanti G. How to interpret meta-analysis models: fixed  
529 effect and random effects meta-analyses. *Evid Based Ment Health.* 2014;17(2):64.  
530 doi:10.1136/eb-2014-101794
- 531 19. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in  
532 causal relationships inferred from Mendelian randomization between complex traits and  
533 diseases. *Nat Genet.* 2018;50(5):693-698. doi:10.1038/s41588-018-0099-7
- 534 20. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the  
535 MR-Egger method. *Eur J Epidemiol.* 2017;32(5):377-389. doi:10.1007/s10654-017-0255-  
536 x
- 537 21. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable  
538 Mendelian randomization in the single-sample and two-sample summary data settings. *Int*  
539 *J Epidemiol.* 2019;48(3):713-727. doi:10.1093/ije/dyy262
- 540 22. Foley CN, Mason AM, Kirk PDW, Burgess S. MR-Clust: Clustering of genetic variants in  
541 Mendelian randomization with similar causal estimates. *Bioinformatics.* 2021;37(4):531-  
542 541. doi:10.1093/bioinformatics/btaa778
- 543 23. Zheng J, Haberland V, Baird D, et al. Phenome-wide Mendelian randomization mapping  
544 the influence of the plasma proteome on complex diseases. *Nat Genet.* 2020;52(10):1122-  
545 1131. doi:10.1038/s41588-020-0682-6
- 546 24. Sun BB, Chiou J, Traylor M, et al. Plasma proteomic associations with genetics and health  
547 in the UK Biobank. *Nature.* 2023;622(7982):329-338. doi:10.1038/s41586-023-06592-6
- 548 25. Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies  
549 predicts complex trait gene targets. *Nat Genet.* 2016;48(5):481-487. doi:10.1038/ng.3538
- 550 26. Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for  
551 searching human genotype-phenotype associations. *Bioinformatics.* 2019;35(22):4851-  
552 4853. doi:10.1093/bioinformatics/btz469
- 553 27. Oscanoa J, Sivapalan L, Gadaleta E, Dayem Ullah AZ, Lemoine NR, Chelala C.  
554 SNPnexus: a web server for functional annotation of human genome sequence variation  
555 (2020 update). *Nucleic Acids Res.* 2020;48(W1):W185-W192. doi:10.1093/nar/gkaa420
- 556 28. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell  
557 types, regulators and target genes for human complex traits and disease. *Nucleic Acids*  
558 *Res.* 2016;44(D1):D877-81. doi:10.1093/nar/gkv1340
- 559 29. Jupiter D, Chen H, VanBuren V. STARNET 2: a web-based tool for accelerating  
560 discovery of gene regulatory networks using microarray co-expression data. *BMC*  
561 *Bioinformatics.* 2009;10:332. doi:10.1186/1471-2105-10-332
- 562 30. Wheeler HE, Shah KP, Brenner J, et al. Survey of the Heritability and Sparse Architecture  
563 of Gene Expression Traits across Human Tissues. *PLoS Genet.* 2016;12(11):e1006423.  
564 doi:10.1371/journal.pgen.1006423
- 565 31. Barbeira AN, Dickinson SP, Bonazzola R, et al. Exploring the phenotypic consequences  
566 of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat*  
567 *Commun.* 2018;9(1):1825. doi:10.1038/s41467-018-03621-1
- 568 32. Araujo DS, Nguyen C, Hu X, et al. Multivariate adaptive shrinkage improves cross-  
569 population transcriptome prediction for transcriptome-wide association studies in



- 570 underrepresented populations. *bioRxiv*. Published online May 20, 2023.  
571 doi:10.1101/2023.02.09.527747
- 572 33. Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting  
573 omics data. *Innovation (Cambridge (Mass))*. 2021;2(3):100141.  
574 doi:10.1016/j.xinn.2021.100141
- 575 34. Aslan AN, Ayhan H, Çiçek ÖF, et al. Relationship between aortic stiffness and the left  
576 ventricular function in patients with prediabetes. *Intern Med*. 2014;53(14):1477-1484.  
577 doi:10.2169/internalmedicine.53.1720
- 578 35. Dec-Gilowska M, Trojnar M, Makaruk B, Mosiewicz-Madejska B, Dzida G, Mosiewicz J.  
579 Local elasticity of the aorta in patients with type 2 diabetes mellitus. *J Int Med Res*.  
580 2020;48(9):300060520952643. doi:10.1177/0300060520952643
- 581 36. Prakash SK, Pedroza C, Khalil YA, Milewicz DM. Diabetes and reduced risk for thoracic  
582 aortic aneurysms and dissections: a nationwide case-control study. *J Am Heart Assoc*.  
583 2012;1(2). doi:10.1161/JAHA.111.000323
- 584 37. Le MTQ, Jamrozik K, Davis TME, Norman PE. Negative Association between Infra-renal  
585 Aortic Diameter and Glycaemia: The Health In Men Study. *European Journal of Vascular  
586 and Endovascular Surgery*. 2007;33(5):599-604. doi:10.1016/j.ejvs.2006.12.017
- 587 38. Zhang Y, Li Y, Dai X, Lin H, Ma L. Type 2 diabetes has a protective causal association  
588 with thoracic aortic aneurysm: a Mendelian randomization study. *Diabetol Metab Syndr*.  
589 2023;15(1). doi:10.1186/s13098-023-01101-1
- 590 39. Li Z, Xiong J, Guo Y, et al. Effects of diabetes mellitus and glycemic traits on  
591 cardiovascular morpho-functional phenotypes. *Cardiovasc Diabetol*. 2023;22(1):336.  
592 doi:10.1186/s12933-023-02079-w
- 593 40. Roychowdhury T, Lu H, Hornsby WE, et al. Regulatory variants in TCF7L2 are  
594 associated with thoracic aortic aneurysm. *Am J Hum Genet*. 2021;108(9):1578-1589.  
595 doi:10.1016/j.ajhg.2021.06.016
- 596 41. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence  
597 of vascular complications among patients with glucokinase mutations and prolonged, mild  
598 hyperglycemia. *JAMA*. 2014;311(3):279-286. doi:10.1001/jama.2013.283980
- 599 42. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular  
600 complications. *Kidney Int Suppl*. 2000;77:S113-9. doi:10.1046/j.1523-1755.2000.07718.x
- 601 43. Fu J, Yu MG, Li Q, Park K, King GL. Insulin's actions on vascular tissues: Physiological  
602 effects and pathophysiological contributions to vascular complications of diabetes. *Mol  
603 Metab*. 2021;52:101236. doi:10.1016/j.molmet.2021.101236
- 604 44. Ziemann SJ, Kass DA. Advanced Glycation End Product Cross-Linking: Pathophysiologic  
605 Role and Therapeutic Target in Cardiovascular Disease. *Congestive Heart Failure*.  
606 2004;10(3):144-151. doi:10.1111/j.1527-5299.2004.03223.x
- 607 45. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic  
608 aneurysms in patients with diabetes may be related to aberrant monocyte-matrix  
609 interactions. *Eur Heart J*. 2008;29(5):665-672. doi:10.1093/eurheartj/ehm557
- 610 46. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic  
611 aneurysms in patients with diabetes may be related to aberrant monocyte-matrix  
612 interactions. *Eur Heart J*. 2008;29(5):665-672. doi:10.1093/eurheartj/ehm557
- 613 47. Singh SN, Vats P, Suri S, et al. Effect of an antidiabetic extract of *Catharanthus roseus* on  
614 enzymic activities in streptozotocin induced diabetic rats. *J Ethnopharmacol*.  
615 2001;76(3):269-277. doi:10.1016/S0378-8741(01)00254-9

- 616 48. Bosco C, Alegana V, Bird T, et al. Exploring the high-resolution mapping of gender-  
617 disaggregated development indicators. *J R Soc Interface*. 2017;14(129):20160825.  
618 doi:10.1098/rsif.2016.0825
- 619 49. Sakai M, Troutman TD, Seidman JS, et al. Liver-Derived Signals Sequentially Reprogram  
620 Myeloid Enhancers to Initiate and Maintain Kupffer Cell Identity. *Immunity*.  
621 2019;51(4):655-670.e8. doi:10.1016/j.immuni.2019.09.002
- 622 50. Fendler W, Rizzo M, Borowiec M, et al. Less but better: cardioprotective lipid profile of  
623 patients with GCK-MODY despite lower HDL cholesterol level. *Acta Diabetol*.  
624 2014;51(4):625-632. doi:10.1007/s00592-014-0567-1
- 625 51. Ren Y, Li L, Wan L, Huang Y, Cao S. Glucokinase as an emerging anti-diabetes target  
626 and recent progress in the development of its agonists. *J Enzyme Inhib Med Chem*.  
627 2022;37(1):606-615. doi:10.1080/14756366.2021.2025362
- 628 52. Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium-glucose cotransporter-2  
629 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients  
630 with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2015;17(10):984-993.  
631 doi:10.1111/dom.12538
- 632 53. Ren Y, Li L, Wan L, Huang Y, Cao S. Glucokinase as an emerging anti-diabetes target  
633 and recent progress in the development of its agonists. *J Enzyme Inhib Med Chem*.  
634 2022;37(1):606-615. doi:10.1080/14756366.2021.2025362
- 635 54. Zhu D, Li X, Ma J, et al. Dorzagliatin in drug-naïve patients with type 2 diabetes: a  
636 randomized, double-blind, placebo-controlled phase 3 trial. *Nat Med*. 2022;28(5):965-973.  
637 doi:10.1038/s41591-022-01802-6
- 638 55. Cropano C, Santoro N, Groop L, et al. The rs7903146 Variant in the TCF7L2 Gene  
639 Increases the Risk of Prediabetes/Type 2 Diabetes in Obese Adolescents by Impairing  $\beta$ -  
640 Cell Function and Hepatic Insulin Sensitivity. *Diabetes Care*. 2017;40(8):1082-1089.  
641 doi:10.2337/dc17-0290  
642

643

644






Figure 1: Flowchart Mendelian Randomization analysis investigating the causal association between glycaemic traits and aortic measurement and diseases. Sample size description for each summary statistic is presented in the table S2.



Cluster 1 Cluster 2 Main results

A)



B)

